Janssen Pharmaceutical Inc.
NEWS
The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain.
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patientsbwith Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Erleada is an androgen receptor inhibitor approved for non-metastatic castration-resistant prostate cancer.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
St Vincent’s Institute of Medical Research in Melbourne, Australia, announced the extension of the research and licensing collaboration agreement with Janssen Pharmaceuticals, Inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, with focus on Alzheimer’s disease treatment.
A number of companies reported clinical trial data last week. Here’s a look.
JOBS
IN THE PRESS